What is the current stock price of COSCIENS Biopharma Inc. (CSCI)?

As of the latest market data, COSCIENS Biopharma Inc. (CSCI) is trading at $2.72. The stock has seen a loss of -6.91% today.

Does COSCIENS Biopharma Inc. (CSCI) pay a dividend?

Based on current data, COSCIENS Biopharma Inc. does not have a confirmed active dividend policy.

What is the market cap of COSCIENS Biopharma Inc.?

The current market capitalization of COSCIENS Biopharma Inc. (CSCI) is approximately unavailable.

CSCI

COSCIENS Biopharma Inc.·Healthcare

2.72

6.915%(−0.13)

Market Closed

2.59

4.779%(−0.13)

After Hours

Last Updated: — ET

52W L: $1.7552W H: $4.61

CSCI NEWS

globenewswire.com

4d ago

COSCIENS Comments on Unusual Market Activity

TORONTO, ONTARIO, April 07, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is issuing this news release in response to unusual market activity. While the Company does not normally comment on market activity or market speculation, the Company confirms that it is not aware of any material undisclosed information relating to the Company that would account for the recent increase in trading activity in, and trading price of, the Company's common shares.

globenewswire.com

Mar 25

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

TORONTO, ONTARIO, March 25, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on the development of natural, plant-based active ingredients, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2025. All amounts in this press release are in U.S. dollars.

globenewswire.com

Mar 5

COSCIENS Provides Strategic Update

TORONTO, ONTARIO, March 05, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”) today announced that the Company has made a strategic decision to cease funding its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH (the “German Subsidiaries”). As a result, the Company expects the German Subsidiaries to commence a structured insolvency process in the near future.

Company Profile

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

1996-07-18

Beta

1.85

Websitewww.cosciensbio.com↗